Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer.
Anderson CM, Lee CM, Saunders DP, Curtis A, Dunlap N, Nangia C, Lee AS, Gordon SM, Kovoor P, Arevalo-Araujo R, Bar-Ad V, Peddada A, Colvett K, Miller D, Jain AK, Wheeler J, Blakaj D, Bonomi M, Agarwala SS, Garg M, Worden F, Holmlund J, Brill JM, Downs M, Sonis ST, Katz S, Buatti JM. Anderson CM, et al. Among authors: brill jm. J Clin Oncol. 2019 Dec 1;37(34):3256-3265. doi: 10.1200/JCO.19.01507. Epub 2019 Oct 16. J Clin Oncol. 2019. PMID: 31618127 Free PMC article. Clinical Trial.
Phase 1b/2a Trial of the Superoxide Dismutase Mimetic GC4419 to Reduce Chemoradiotherapy-Induced Oral Mucositis in Patients With Oral Cavity or Oropharyngeal Carcinoma.
Anderson CM, Sonis ST, Lee CM, Adkins D, Allen BG, Sun W, Agarwala SS, Venigalla ML, Chen Y, Zhen W, Mould DR, Holmlund JT, Brill JM, Buatti JM. Anderson CM, et al. Among authors: brill jm. Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):427-435. doi: 10.1016/j.ijrobp.2017.10.019. Epub 2017 Oct 16. Int J Radiat Oncol Biol Phys. 2018. PMID: 29174131 Free PMC article. Clinical Trial.
Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study.
DiPersio JF, Erba HP, Larson RA, Luger SM, Tallman MS, Brill JM, Vuagniaux G, Rouits E, Sorensen JM, Zanna C. DiPersio JF, et al. Among authors: brill jm. Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):443-9. doi: 10.1016/j.clml.2015.02.020. Epub 2015 Mar 5. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25842225 Free PMC article. Clinical Trial.
Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study.
Hurwitz HI, Smith DC, Pitot HC, Brill JM, Chugh R, Rouits E, Rubin J, Strickler J, Vuagniaux G, Sorensen JM, Zanna C. Hurwitz HI, et al. Among authors: brill jm. Cancer Chemother Pharmacol. 2015 Apr;75(4):851-9. doi: 10.1007/s00280-015-2709-8. Epub 2015 Feb 27. Cancer Chemother Pharmacol. 2015. PMID: 25716544 Free PMC article. Clinical Trial.
Handle medical record with care.
Brill JM. Brill JM. Am Nurse. 1990 May;22(5):47, 51. Am Nurse. 1990. PMID: 2344101 No abstract available.
Risk management is team effort.
Brill JM. Brill JM. Am Nurse. 1990 Mar;22(3):34. Am Nurse. 1990. PMID: 2321861 No abstract available.
11 results